BELGIUM; FRANCE —Valerio Therapeutics has executed definitive agreements to acquire one hundred percent of Etherna Immunotherapies for an enterprise value of EUR 30 million. This transaction is underpinned by a successfully priced EUR 40.25 million private investment in public equity involving both new and existing institutional backers. The capital injection is designated to fund the cash component of the acquisition, advance internal clinical pipelines, and scale good manufacturing practice production capabilities. Shareholder ratification is anticipated in the fourth quarter, with irrevocable voting commitments already securing a majority threshold.
This strategic consolidation directly addresses a persistent pharmacological bottleneck in the biotechnology sector: the inability of conventional messenger RNA therapies to efficiently target tissues beyond the liver. By merging proprietary cell-targeting conjugates with advanced lipid nanoparticle formulation expertise, the combined entity aims to establish a fully integrated development engine. This vertical integration is designed to accelerate the clinical translation of next-generation nucleic acid medicines for a broader spectrum of systemic diseases.
Valerio Therapeutics is a France-based biotechnology enterprise listed on Euronext Growth, specializing in the discovery of precision-guided RNA therapeutics. Etherna Immunotherapies is a Belgium-based platform company possessing over a decade of specialized expertise in messenger RNA chemistry and lipid nanoparticle manufacturing. The transaction impacts the European life sciences landscape, particularly stakeholders focused on specialized drug delivery mechanisms and contract development manufacturing infrastructure.
For investors and market participants, this development signals a calculated shift toward asset consolidation within the highly competitive RNA therapeutics market. The structured financing, which includes a twenty-five percent discount to the recent volume-weighted average price, provides immediate liquidity while aligning the interests of major existing shareholders. Furthermore, the acquisition grants Valerio direct control over critical manufacturing infrastructure, reducing external supply chain dependencies and enhancing long-term margin potential as its proprietary clinical candidates progress toward regulatory submission.
